Gilead Sciences Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Alrighty. Good afternoon, everyone. I hope day two of our London Healthcare Conference is going well. Again, thrilled to see the turnout, and I hope everyone's meetings are going as well as we hope. My name's Akash Tewari. I lead our pharma and biotech research efforts within the firm. I have the pleasure of hosting the Gilead management team. Dan and Andy, it's really such a pleasure to have you. Why don't I hand it off to you for some opening remarks, and then we'll get started?
Sure. Thank you very much for having us here. Delighted to be here with all of you. Andy and I are here representing the team, I think, that has done some pretty extraordinary work over the past many years, and really, I think, a strong time in the evolution of the Gilead story, in that we have, I think, very much strengthened the HIV business overall at Gilead over the past many years, and added two substantial new areas of focus for us. Obviously, one is oncology and one is inflammation. I think we're in a very strong position. We're coming off of the strongest growth we've had in more than a decade in the third quarter, driven really across the therapeutic areas.
Strong growth in HIV, strong growth in oncology, in particular in our TRODELVY business, and then LIVDELZI on the PBC side, the beginning of our inflammation approach. We feel really good about where we're at. I would say that we also feel we're at the very beginning of unpacking the diversification story, the diversification story within HIV and the diversification story outside of HIV. We're firmly committed to just a continual series of innovations between now and really the next. The only major patent cliff we have right now is 2036 in BIKTARVY, and we feel we're in a very good position to strengthen and diversify our HIV treatment business well before the 2036 patent. That, combined with the other two therapeutic areas, puts us in a very strong position, and we're very committed to running a very operationally efficient business as well.
We expect good, strong growth on the top and bottom line moving forward. Look forward to your questions.
I really appreciate it. I mean, I would agree, you have two foundational assets, oncology and then in I&I with the oral ENTYVIO. Tubulis, that's a platform you can really build on. Let's start with I&I. You had really interesting data. It certainly looks like an active molecule. It can rival what we've seen with the biologics. So much, I feel like, of what your team goes into markets, it's not just the asset, but it's really the strategy and how you see it playing out that might be different than others. You have an oral ENTYVIO. You also recently in-licensed an oral IL-23. So, two oral assets. What do you think the market misunderstands when you can deliver oral biologic efficacy that is obvious to your team right now?
Can you talk a bit about what your plan of attack is for mild patients, right? Going up the disease category, so not just for late-stage patients, but with an oral therapy. Could we see your drug actually expand the market and grow it in a way that maybe we don't appreciate right now?
Sure. Maybe just to give a little context, and I invite Andy in to add, obviously, on this. When we started this journey about eight years ago and we decided to expand into oncology and inflammation, it was really around two key strengths we had at the company at the time. One was immunology, biological expertise, but the other one at the time was small molecules. Since then, by the way, we've expanded. We're the world leaders in cell therapy. We have a very strong biologic base, and the combination of biologics and small molecules gives us a unique position in the ADC market as well.
When we started this, back to your question, it was really around how do we leverage our small molecule chemistry to approach known targets in inflammation, but with unique molecules that could not only be effective as single agents, but very importantly, because we know we're a new entrant to the space, the potential to combine multiple agents in inflammation, which has been something that has escaped much of the science of this area. We all know we've been dealing with kind of efficacy ceilings in many disease states across inflammation, and that's largely because of a single-agent tolerance level. Being able to combine agents, we always thought would help get us to a different level of efficacy at the end of the day. So, it wasn't just about taking an injectable and turning it into a pill.
It was about taking a target and allowing it to be combinable to get through an efficacy barrier. Now, what we've seen so far, and it's early days, but the two data sets that are probably out there in our work, phase II, are the IRAK4 and the alpha4 beta7. To your question around alpha4 beta7, we think it's a very attractive data set for a phase II. It looks like potentially IV-level efficacy or injectable-level efficacy in a pill with a very good tolerability profile. We will pursue that in monotherapy as we approach an alternative for patients with UC and IBD, but we'll also be pursuing it in parallel in combination. It could go with a variety of different mechanisms.
We do think IL-23 is a particularly good mechanism, but it's not the only mechanism, which is why we in-license a product in early IL-23 that we think is very interesting. I don't want you to believe that that's the only combination we could imagine alpha4 beta7 working with. We could look at other IL-23s. We could look at other mechanisms moving forward. To your question on kind of moderate disease moving forward, I think first of all, the tolerability profile allows one to think earlier in more moderate stage diseases, because benefit-risk, obviously, in this population, the milder you get, the more you need a better tolerability profile, which we think both, frankly, the alpha4 beta7 and potentially the IL-23, either as a monotherapy or in combination, have the type of profiles to get into that earlier stage moderate patient. If you want to add on.
Yeah, I mean, first of all, Akash, thanks for having us and thanks for the question. Look, I don't think there's a lot. When you say, "What does the market not understand that we understand?" I think it's the. People knew that we were building an inflammation franchise, but they just weren't following it as closely because we didn't yet have phase II data. In the last couple of weeks, you now have the oral alpha4 beta7 data. You have the IRAK4 small molecule. We also have an IRAK4 degrader, but IRAK4 small molecule data that was at ACR and cutaneous lupus this weekend. That's very exciting. Small dataset, phase kind of II-A dataset, but very exciting. We're going to have our gamgertamig, which is our B-cell depleter. This is a BCMA CD3 T-cell depleter. That data will be at ASH. That's in partnership with our partner, Lakefront Biotherapeutics.
There's four or five other programs around it. I think the world knew that we were building this, but they're just now kind of paying attention as we're developing more data. Again, we have a number of programs across Kite that are also working in autoimmune with both anito-cel as well as a CD19, CD20 bispecific. There's just a lot happening here, and the datasets are just starting to come out, which is then giving people a glimpse. I think to Dan's point, the last thing I'll say is on monotherapy, or on the mild disease, both the oral alpha4 beta7 as a monotherapy may be able to kind of look at more mild disease. Then part of what we really liked about this IL-23 peptide that we're acquiring from a company in China is that it's very potent.
It has potential for once-monthly oral dosing. When you think of that as a monotherapy, whether it's in dermatological conditions or in UC, it could be something that's used across the spectrum, including potentially in mild disease.
Understood. Dan, you said something pretty provocative there, because you said, "Look, we can combine with the oral IL-23 we just got, but there could be other IL-23s we're looking at." Because again, I think a lot of it is, I think to Andy's point, it's we understand the targets. We know these are big markets. It's like, well, when are we going to start getting revenues from Gilead, right? I think that's really where there's the desire. I can't help but think there are other companies that have assets already on the market that also have really a dominant presence in I&I, because you have to build out that sales force as well, where I feel like your team could leverage.
Can you expand a bit more about with the oral ENTYVIO, how aggressively are you looking at on the market or near to market oral combination options outside of the IL-23 that you recently in-licensed?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
